GLWL-01

PreclinicalSmall molecule

NNational Institute on Drug Abuse (NIDA)

GLWL-01 is one of 16 small molecule programs targeting Bariatric Surgery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bariatric SurgeryCompleted

Bariatric SurgeryPreclinical

Completed

Competition

Competitive Landscape

17 competitors in Bariatric Surgery

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Approved

1 2

Adipex-P

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

4 3

Topamax

WWim Janssens

Approved

3 4

Cyklokapron

JJ Molner

Approved

3 5

IC-Green

PProvepharm SAS

Approved

2 6

Spravato

WWim Janssens

Approved

1 7

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 8

Glucophage

EMD Serono

Phase 3

1 9

Gas-X

PPortuguese Oncology Institute, Coimbra

Phase 3

1 10

Naltrexone Pill

YYale University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prader-Willi syndrome1 trial

A Study of GLWL-01 in Patients With Prader-Willi Syndrome

Completed·GGLWL Research Inc.·Phase 2·NCT03274856·19 enrolled

Alcohol Use Disorder1 trial

Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 1/2·NCT03896516·21 enrolled

Bariatric Surgery1 trial

Investigating the Role of Ghrelin in Regulating Appetite and Energy Intake in Patients Following Bariatric Surgery (BARI-INSIGHT)

Completed·UUniversity College, London·N/A·NCT03641417·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for GLWL-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLWL-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLWL-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute on Drug Abuse (NIDA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute on Drug Abuse (NIDA)

GLWL-01

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prader-Willi syndrome1 trial

Alcohol Use Disorder1 trial

Bariatric Surgery1 trial

References

Drug Info

Quick Facts

Related News